A prospective controlled study reported that adding hepatic arterial infusion chemotherapy to lenvatinib plus a PD-1 inhibitor roughly doubled median overall survival in advanced liver cancer patients with portal vein tumor thrombosis. The study was published in BMC Medicine. The regimen combines locoregional cytotoxic delivery with systemic targeted therapy and checkpoint inhibition, underscoring continued momentum for multi-modality strategies in high-risk liver oncology subgroups.